Bristol Myers Squibb acquires RayzeBio for $4.1bn

2024-02-27

临床1期临床3期并购

Bristol Myers Squibb acquires RayzeBio for $4.1bn

Preview

来源: Pharmaceutical Technology

Through the RayzeBio acquisition, BMS will gain access to an RPT manufacturing facility. Credit: JHVEPhoto / Shutterstock.com.

Bristol Myers Squibb (BMS) has announced the conclusion of its acquisition of RayzeBio, a clinical-stage radiopharmaceutical company, for $4.1bn.

RayzeBio is now a wholly owned BMS subsidiary.

The companies signed an agreement for the acquisition in December 2023 in which BMS would acquire all outstanding shares of RayzeBio.

The acquisition introduces a radiopharmaceutical therapeutics (RPTs) pipeline to BMS, including the lead programme, RYZ101 (²²⁵Ac-DOTATATE). This therapy is designed to target somatostatin receptor (SSTR)2, which is overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and extensive stage small cell lung cancer (ES-SCLC).

A Phase III clinical trial is currently enrolling subjects to assess RYZ101 in individuals with SSTR-positive GEP-NETs SSTR-positive GEP-NETs who have previously received treatment with lutetium-177-based somatostatin therapies.

See Also:CC-98633 by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

CC-98633 by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

Interim data from the Phase Ib portion of the ACTION-1 clinical trial for RYZ101 have shown encouraging tolerability and efficacy.

A Phase Ib trial is also progressing to assess RYZ101 as a first-line treatment for ES-SCLC in combination with standard-of-care therapy.

The acquisition also includes an RPT manufacturing facility which will commence operations in the first half of 2024.

BMS CEO Chris Boerner stated: “We are excited to complete this transaction, which adds RPTs, one of the fastest-growing new modalities for treating patients with solid tumours.

“By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s growth in the back half of the decade and beyond. RayzeBio is a pioneer in the application of this novel modality, and we look forward to working with their talented team to accelerate their preclinical and clinical programmes for the benefit of patients around the world.”

The latest deal comes after BMS entered a $674m collaboration with US deep tech company VantAI.

The partnership will focus on using VantAI’s generative AI platform to design and develop molecular glues – a small molecule that induces or stabilises interactions between two proteins that would not normally go together.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构